41870-24-0

Basic information

• Product Name: 4-METHOXY-3-NITROBENZYL ALCOHOL 97
• Synonyms: 4-METHOXY-3-NITROBENZYL ALCOHOL 97;BenzeneMethanol, 4-Methoxy-3-nitro-;4-Methoxy-3-nitrobenzyl alcohol 97%
• CAS NO: 41870-24-0
• Molecular Formula: C₈H₉NO₄
• Molecular Weight: 183.162
• Product Categories: Alcohols;C7 to C8;Oxygen Compounds;Building Blocks;C7 to C8;Chemical Synthesis;Organic Building Blocks;Oxygen Compounds
• Mol File: 41870-24-0.mol
• Article Data: 14

Chemical Properties

• Melting Point: 68-71 °C(lit.)
• Boiling Point: 367.3°C at 760 mmHg
• Flash Point: 175.9°C
• Appearance: /
• Density: 1.316g/cm³
• Vapor Pressure: 4.84E-06mmHg at 25°C
• Refractive Index: 1.574
• PKA: 13.57±0.10(Predicted)
• CAS DataBase Reference: 4-METHOXY-3-NITROBENZYL ALCOHOL 97(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHOXY-3-NITROBENZYL ALCOHOL 97(41870-24-0)
• EPA Substance Registry System: 4-METHOXY-3-NITROBENZYL ALCOHOL 97(41870-24-0)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 41870-24-0(Hazardous Substances Data)

Usage

General Description

4-Methoxy-3-nitrobenzyl alcohol is an organic building block.

InChI:InChI=1/C8H9NO4/c1-13-8-3-2-6(5-10)4-7(8)9(11)12/h2-4,10H,5H2,1H3

Upstream product

• 31680-08-7 4-methoxy-3-nitrobenzaldehyde 
• 41833-13-0 4-hydroxymethyl-2-nitrophenol 
• 74-88-4 methyl iodide 
• 186581-53-3 diazomethane 
• 123-11-5 4-methoxy-benzaldehyde 
• 105-13-5 4-Methoxybenzyl alcohol 
• 3011-34-5 4-hydroxy-3-nitrobenzaldehyde 
• 89-41-8 4-methoxy-3-nitrobenzoic acid 
• 88-75-5 2-hydroxynitrobenzene 
• 91-23-6 2-Nitroanisole 
• 6378-19-4 4-methoxy-3-nitrobenzyl chloride 

Downstream Products

• 89-41-8 4-methoxy-3-nitrobenzoic acid 
• 113928-90-8 (3-amino-4-methoxyphenyl)methanol 
• 31680-08-7 4-methoxy-3-nitrobenzaldehyde 
• 6378-19-4 4-methoxy-3-nitrobenzyl chloride 
• 61010-34-2 3-nitro-4-methoxybenzyl bromide 
• 1330633-58-3 (E)-2'-methoxystyryl-4-methoxy-3-aminobenzylsulfone 
• 1330633-59-4 (E)-4'-methoxystyryl-4-methoxy-3-nitrobenzylsulfone 
• 1330633-60-7 (E)-4'-methoxystyryl-4-methoxy-3-aminobenzylsulfone 
• 1330633-62-9 (E)-2',4'-dimethoxystyryl-4-methoxy-3-aminobenzylsulfone 
• 1330633-63-0 (E)-2',5'-dimethoxystyryl-4-methoxy-3-aminobenzylsulfone 
• 1330633-68-5 (E)-2',4',5'-trimethoxystyryl-4-methoxy-3-aminobenzylsulfone 
• 1330633-69-6 (E)-3',4',5'-trimethoxystyryl-4-methoxy-3-aminobenzylsulfone 
• 1330633-71-0 (E)-2',6'-dimethoxy-4'-hydroxystyryl-4-methoxy-3-nitrobenzylsulfone 
• 1330633-72-1 (E)-2',6'-dimethoxy-4'-hydroxystyryl-4-methoxy-3-aminobenzylsulfone 

Relevant articles and documents

Synthesis and antitumor effects of novel benzyl naphthyl sulfoxide/sulfone derivatives derived from Rigosertib

In this work, a series of novel benzyl naphthyl sulfoxides/sulfones derived from Rigosertib were designed and synthesized as potential antitumor agents. The in vitro cytotoxicity against four human cancer cell lines (HeLa, MCF-7, HepG2 and SCC-15) and two normal human cell lines (HUVEC and 293T) indicated that some of the sulfones and sulfoxides possessed potent antineoplastic activity that reached nanomolar levels and relatively low toxicity to normal cells. Among them, (2-methoxy-5-((naphthalen-2-ylsulfonyl)methyl)phenyl)glycine (15b) was found to be a promising antitumor drug candidate that could significantly inhibit tumor cell migration and induce tumor cell apoptosis via the p53-Bcl-2-Bax signaling pathway at nanomolar concentrations.

Platinum-Based Modification of Styrylbenzylsulfones as Multifunctional Antitumor Agents: Targeting the RAS/RAF Pathway, Enhancing Antitumor Activity, and Overcoming Multidrug Resistance

Inhibiting/disturbing the RAS/RAF pathway may benefit the treatment of cancer and overcome the resistance. Utilizing such a pathway as the target, nine styrylbenzylsulfone derivatives generated from the platinum-based modification of the side chain of Rig

Synthesis and Biological Evaluation of 1,2,3-triazole tethered Pyrazoline and Chalcone Derivatives

A series of pyrazoline derivatives and corresponding chalcone intermediates with substituents same as combretastatin-A4(CA-4) conjugated with triazole nucleus has been synthesized and evaluated for their anticancer potential. Sulphorhodamine B(SRB) assay indicated compound 12c to be the most active compound from the series with GI50 value of 6.7 μm against the human liver carcinoma cell line HepG2. Interestingly, the intermediate 11c exhibited more promising cytotoxicity demonstrating GI50 value of 1.3 μm against the prostate cancer cell line DU145. Compounds 11c and 12c caused accumulation of cells in G2/M phase and inhibited tubulin polymerization. Furthermore, these compounds reduce the mitochondrial membrane potential and activate caspases 3 and 9, thereby indicating their ability to trigger apoptosis.